Patents Assigned to Pfizer
  • Patent number: 4835192
    Abstract: Compounds having the formula ##STR1## R.sub.1 is hydrogen, benzyl or alkanoyl, X is C.sub.2-4 alkylene; andZ-W is alkyl, phenylalkyl or pyridylalkyl which can have an oxygen atom as part of the alkyl chain and their use as CNS agents, antidiarrheals and antiemetics. Processes for their preparation and intermediates therefor are described.
    Type: Grant
    Filed: February 4, 1988
    Date of Patent: May 30, 1989
    Assignee: Pfizer Inc.
    Inventors: Michael R. Johnson, Lawrence Melvin, Jr.
  • Patent number: 4834755
    Abstract: A novel prosthesis for use in repairing or replacing soft tissue is disclosed, which comprises a triaxially-braided fabric element having interwoven first, second and third sets of fibers, with the fibers of the second and third sets being oriented at substantially the same acute braiding angle with respect to the fibers of the first set. An elongated ligament prosthesis exhibiting the desired properties of high strength and high elasticity may be prepared by selecting high elasticity fibers for the first set, orienting said first set of fibers in the longitudinal direction of the prosthesis and selecting fibers having high yield strength and high Young's modulus for the second and third sets. A tubular prosthesis in which high elasticity fibers are oriented in the longitudinal direction is highly suitable for use as a vascular prosthesis. A prosthesis of the invention may also be manufactured in the form of a prosthetic heart valve leaflet.
    Type: Grant
    Filed: March 4, 1985
    Date of Patent: May 30, 1989
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: Thomas A. Silvestrini, Joseph E. Laptewicz, Jr.
  • Patent number: 4831031
    Abstract: Arylpiperazinyl-ethyl(or butyl)-heterocyclic compounds and their pharmaceutically acceptable acid addition salts are neuroleptic agents. They are useful in the treatment of psychotic disorders.
    Type: Grant
    Filed: January 22, 1988
    Date of Patent: May 16, 1989
    Assignee: Pfizer Inc.
    Inventors: John A. Lowe, III, Arthur A. Nagel
  • Patent number: 4830860
    Abstract: A matrix device for controlled release of at least one active agent to an ambient environment, said matrix comprising an active agent--or agents--containing polymer which has been subjected to tensile stress. Included is a laminate device comprising at least one matrix as core sheet, said core sheet or sheets comprising the active agent or agents in a polymer matrix which has been subjected to stress and, in a further embodiment, a porosity enhancing agent in admixture with said agent; the core sheet or sheets being alternately sandwiched or interposed between coextensive inert polymeric films substantially impermeable to said environment and to said agent or agents, said device being perforated by one or a plurality of macroholes extending through said sheets and said films. Also included are methods for making such a device.
    Type: Grant
    Filed: October 30, 1986
    Date of Patent: May 16, 1989
    Assignee: Pfizer Inc.
    Inventor: Gautam R. Ranade
  • Patent number: 4830989
    Abstract: A continuous, monofilamentous, alkali-resistant glass fiber especially useful in cementitious products is conveniently prepared from a glass-forming composition comprising a magnesium silicate such as talc and a calcium carbonate such as limestone. Either the fiber itself or a strand comprising a plurality of the fiber is advantageously coated with an alkali-resistant polymer such as butadiene-styrene to provide additional alkali resistance.
    Type: Grant
    Filed: February 22, 1988
    Date of Patent: May 16, 1989
    Assignee: Pfizer Inc.
    Inventors: Nikhil C. Trivedi, John D. Mackenzie
  • Patent number: 4831059
    Abstract: Compounds having the formula ##STR1## R.sub.1 is hydrogen, benzyl or an ester moiety; Y is --CH(R.sub.2 ")CH(R.sub.2)-- or --CH(R.sub.3)CH hd 2--;R.sub.2 " is hydrogen or methyl;R.sub.2 is OH or X-substituted (C.sub.1-6)alkyl;R.sub.3 is OH, cyano or X-substituted (C.sub.1-3)alkyl;X is --OR.sub.6, --SR.sub.6, --S(O)R.sub.6, --S(O).sub.2 R.sub.6, --NR.sub.6 R.sub.7, --COOR.sub.7, --CONR.sub.7 R.sub.8 or oxo;with the proviso that when X is --NR.sub.6 R.sub.7, --COOR.sub.7 or --CONR.sub.7 R.sub.8, said group is located on the terminal carbon atom of R.sub.2 or R.sub.3 ;R.sub.6 is hydrogen, (C.sub.1-6)alkyl or acetyl;each of R.sub.7 and R.sub.8 is hydrogen or (C.sub.1-6)alkyl;s is an integer of 1 or 2;with the proviso that when R.sub.6 is acetyl, R.sub.7 is hydrogen and X is other than S(O)R.sub.6 or S(O).sub.2 R.sub.6 ;Z-W is alkyl, phenylalkyl or pyridylalkyl which can have an oxygen atom as part of the alkyl chain, and their use as CNS agents, antidiarrheals and anti-emetics.
    Type: Grant
    Filed: February 23, 1988
    Date of Patent: May 16, 1989
    Assignee: Pfizer Inc.
    Inventors: Michael R. Johnson, Lawrence S. Melvin, Jr.
  • Patent number: 4829062
    Abstract: A series of novel oxyalkyl ether derivatives of various enolic oxicam compounds have been prepared, including certain novel enol oxyalkyl ethers of 4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam). These particular compounds are useful in theraphy as prodrug forms of the known anti-inflammatory and analgesic oxicams.
    Type: Grant
    Filed: December 22, 1987
    Date of Patent: May 9, 1989
    Assignee: Pfizer Inc.
    Inventors: Joseph G. Lombardino, Anthony Marfat
  • Patent number: 4828562
    Abstract: An adjustable housing suitable to be used with another housing and with a synthetic ligament so as to provide (for example) an anterior cruciate ligament prosthesis system for a knee joint is provided. The adjustable housing features an interior having a step shoulder located therein. A set screw in the housing fixes the synthetic ligament at a desired level of tension. The system has many significant advantages including (but not limited to) being able to withstand very high loads and being able to be retensioned repeatedly and easily without replacing the artificial ligament.
    Type: Grant
    Filed: February 4, 1988
    Date of Patent: May 9, 1989
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventor: Robert V. Kenna
  • Patent number: 4829071
    Abstract: Novel 5-alkanesulphonamido-2-[N-(alkanesulphonamidoheterocyclicmethyl-N-methylam ino]indane compounds have been prepared, including their pharmaceutically acceptable salts and various key novel intermediates therefor. The heterocyclic moiety present in these compounds is a benzofused heterocyclic group derived from either benzofuran or quinoline, and it is attached to the adjacent methyl group of the molecule by means of the available ring carbon atom which is situated alpha to the hetero atom. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. The most preferred member compound is 5-methylanesulphonamido-2-[N-(5-methanesulphonamidobenzofur-2-ylmethyl)-N- methylamino]idane. Methods for preparing these compounds from known starting materials are provided.
    Type: Grant
    Filed: February 22, 1988
    Date of Patent: May 9, 1989
    Assignee: Pfizer Inc.
    Inventors: John E. Arrowsmith, Peter E. Cross
  • Patent number: 4827919
    Abstract: A femoral spacer for positioning a femoral prosthesis is disclosed comprising a hollow body portion having an outside surface and an inside surface. The outside surface is adapted to contact the intramedullary canal wall, and the inside surface is adapted to contact the proximal portion of the prosthesis such that the prosthesis is substantially centered within the intramedullary canal.
    Type: Grant
    Filed: October 27, 1986
    Date of Patent: May 9, 1989
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventors: James L. Barbarito, William J. Cymbaluk, Jr., Matthew P. Poggie
  • Patent number: 4826833
    Abstract: Beta-lactamase inhibiting compounds of the formula ##STR1## or a pharmaceutically acceptable acid addition or carboxylate salt thereof; where n is zero, 1 or 2; X.sub.3 is H or Br, R.sup.1 is H, the residue of certain carboxy-protecting groups or the residue of an ester group readily hydrolyzable in vivo; one of R.sup.12 and R.sup.13 is H and the other is vinyl, certain aryl, alkylthio, alkylsulfonyl or certain heterocyclyl, aminomethyl, thiocarboxamido or amidino groups; one or R.sup.2 and R.sup.3 is H and the other is as disclosed for the other of R.sup.12 and R.sup.13, or is Cl or CH.sub.2 OH, and R.sup.18 is H or certain acyl groups; intermediates useful in their production, methods for their preparation and use, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 30, 1986
    Date of Patent: May 2, 1989
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Patent number: 4821802
    Abstract: Aqueous gel-forming compositions are prepared by reacting for 1-10 hours at 50.degree.-95.degree. C., melamine, formaldehyde and a sulfurous acid salt with the optional addition of a gel-modifying agent and/or a gelling agent which is added to the composition immediately prior to use.
    Type: Grant
    Filed: September 1, 1988
    Date of Patent: April 18, 1989
    Assignee: Pfizer Inc.
    Inventors: Clifford N. Meltz, Gordon D. Gruetzmacher, Ping W. Chang
  • Patent number: 4822793
    Abstract: Compounds of the formula: ##STR1## or a salt thereof, wherein "Het" is a group of the formula: ##STR2## in which R.sup.1 is attached to position "a" or "b" of the benzene ring and R and R.sup.1, which are the same, are --NHSO.sub.2 (C.sub.1 -C.sub.4 alkyl), --NH.sub.2 or --NO.sub.2.The compounds in which R and R.sup.1 are --NHSO.sub.2 (C.sub.1 -C.sub.4 alkyl) are cardiac antiarrhythmic agents. The compounds in which R and R.sup.1 are --NO.sub.2 and --NH.sub.2 are synthetic intermediates.
    Type: Grant
    Filed: March 21, 1988
    Date of Patent: April 18, 1989
    Assignee: Pfizer Inc.
    Inventors: John E. Arrowsmith, Peter E. Cross
  • Patent number: 4814342
    Abstract: Polypeptides and derivatives thereof containing nor-statine and nor-cyclostatine are useful for inhibiting the angiotensinogen-cleaving action of the enzyme renin.
    Type: Grant
    Filed: October 23, 1987
    Date of Patent: March 21, 1989
    Assignee: Pfizer Inc.
    Inventors: Dennis J. Hoover, Robert L. Rosati, Ronald T. Wester
  • Patent number: 4812471
    Abstract: Hypoglycemic 5-chromanyl, 2,3-dihydro-5-benzo[b]-furanyl, 5-pyridyl, 5-quinolyl, 5-pyrrolyl, 5-indolyl, 5-thiazolyl, 5-oxazolyl, 5-isothiazolyl and 5-isoxazolyl oxazolidine-2.4-diones and the pharmacetically-acceptable salts thereof; certain 3-acylated derivatives thereof; a method of treating hyperglycemic animals therewith; and intermediates useful in the preparation of said compounds.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: March 14, 1989
    Assignee: Pfizer Inc.
    Inventor: Rodney C. Schnur
  • Patent number: 4812455
    Abstract: An improved antiinflammatory composition and method of treating inflammation which employs a combination of antiinflammatory piroxicam, or a pharmaceutically acceptable salt thereof, with analgesic acetaminophen, antidepressant doxepin, bronchodilator pirbuterol, minor tranquilzer diazepam, or antihypertensive trimazosin.
    Type: Grant
    Filed: April 11, 1988
    Date of Patent: March 14, 1989
    Assignee: Pfizer Inc.
    Inventors: Thomas C. Crawford, Stanley L. Keely, David L. Larson, Joseph G. Lombardino, James J. Maciejko
  • Patent number: 4808591
    Abstract: 8-(2-Pyrimidylsulfinyl)quinolines, inhibitors of the H.sup.+ /K.sup.30 ATPase enzyme, are useful in the treatment of ulcers.
    Type: Grant
    Filed: February 16, 1988
    Date of Patent: February 28, 1989
    Assignee: Pfizer Inc.
    Inventor: Conrad Santini
  • Patent number: 4808601
    Abstract: Certain novel 2-oxindole compounds, having an acyl substituent at both the 1-position and the 3-position, are inhibitors of the cyclooxygenase (CO) and lipoxygenase (LO) enzymes, and are useful as analgesic agents and antiinflammatory agents in mammalian subjects. These 1,3-diacyl-2-oxindole compounds are of particular value for acute administration for ameliorating pain in human patients recovering from surgery or trauma, and also for chronic administration to human subjects for alleviating the symptoms of chronic diseases such as rheumatoid arthritis and osteoarthritis.
    Type: Grant
    Filed: May 19, 1988
    Date of Patent: February 28, 1989
    Assignee: Pfizer Inc.
    Inventor: Saul B. Kadin
  • Patent number: 4808597
    Abstract: Certain carboxylic acids of the formula ##STR1## and the pharmaceutically-acceptable salts thereof, and certain esters and amides thereof, are useful for inhibiting the degradation of articular cartilage when administered to a mammalian subject afflicted with an arthritic disease. X is O, S, SO, SO.sub.2, NH, NCH.sub.3 or NCOCH.sub.3 ; and n is zero or one.
    Type: Grant
    Filed: June 2, 1988
    Date of Patent: February 28, 1989
    Assignee: Pfizer Inc.
    Inventors: William W. Hoffman, Allen R. Kraska
  • Patent number: 4806536
    Abstract: A series of novel 4-substituted piperazinyl-pyridine and 4-substituted piperazinyl-imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the 4-substituent is a lower phenylalkyl group or a derivative thereof further substituted on the phenyl moiety by a sulphamoyl or sulphonylamino group or by a nitro, amino or acetamido group. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrythmias. The most preferred member compound of the series is N-{4-[1-hydroxy-2-(4-[4-pyridinyl]-1-piperazinyl)ethyl]phenyl} methanesulphonamide. Methods for preparing all these compounds from known starting materials are provided.
    Type: Grant
    Filed: February 2, 1987
    Date of Patent: February 21, 1989
    Assignee: Pfizer, Inc.
    Inventors: Peter E. Cross, Roger P. Dickinson